Association of adjunctive Clostridium butyricum supplementation with eradication outcomes and safety during Helicobacter pylori eradication therapy in adolescents: A multicenter retrospective cohort study
This multicenter retrospective cohort study of 1,169 adolescents suggests that adjunctive *Clostridium butyricum* supplementation during vonoprazan-based *Helicobacter pylori* eradication therapy is safe and associated with numerically higher first-line eradication rates, although the difference did not reach statistical significance.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, a tiny bacterium called Helicobacter pylori has lived quietly inside the stomachs of roughly half the people on Earth. Usually acquired during childhood, this infection rarely causes immediate trouble, but it lingers for a lifetime unless actively removed. Over time, this persistent guest can irritate the stomach lining, leading to ulcers or, in some cases, increasing the risk of stomach cancer. Because the infection often starts young, doctors in Japan have begun screening teenagers to catch and treat it early, hoping to prevent serious disease before it ever begins. The standard treatment involves a powerful combination of medicines designed to kill the bacteria, but these drugs can sometimes upset the stomach, causing diarrhea or pain, which might make patients stop taking them before the job is done. To help, some doctors have tried adding probiotics—beneficial bacteria that support gut health—to the treatment mix, hoping they would make the cure work better and feel easier to take.
A large team of researchers in Japan recently looked back at the medical records of 1,169 teenagers who underwent this standard treatment between 2016 and 2025. They wanted to see if adding a specific probiotic called Clostridium butyricum, sold under the brand name Miya-BM, actually helped. In this study, the teenagers were not randomly assigned to take the probiotic; instead, they received it based on the standard rules of the hospital or clinic they visited. Some received no probiotic at all, while others took either four or six tablets of the probiotic every day alongside their main medicine. The researchers checked two main things: whether the bacteria were successfully eliminated from the stomach, and whether the patients experienced any uncomfortable side effects like diarrhea or stomach pain.
The results showed that the treatment worked very well across the board, but there was a noticeable difference between the groups. Among the teenagers who did not take the probiotic, about 73 out of every 100 were successfully cured of the infection. In contrast, those who took the probiotic tablets saw success rates rise to 85 out of every 100. While this improvement was clear in the numbers, the researchers noted that it did not reach the strict statistical threshold usually required to declare a definitive scientific victory. However, the data strongly suggested that the probiotic might offer a real benefit. Perhaps even more telling was the behavior of the patients themselves. The teenagers who took the probiotic were significantly more likely to finish their entire course of medication without missing a dose. In the group taking six tablets a day, every single patient with a record completed all their doses, compared to fewer than 92 percent in the group that took no probiotic at all.
When it came to safety, the addition of the probiotic did not cause any new problems. The rates of diarrhea, stomach pain, and other gastrointestinal complaints were nearly identical across all three groups. This is a crucial finding because it means the probiotic did not make the treatment harder to tolerate, nor did it introduce new risks. The researchers also looked at what happened when the first treatment failed and a second round of medicine was needed. In these cases, the success rates were extremely high for everyone, exceeding 94 percent, regardless of whether they had taken the probiotic during the first attempt. This suggests that the probiotic's main role, if any, is to support the initial treatment rather than to fix a failed one.
The study concludes that adding this specific probiotic to the standard treatment for teenagers appears to be safe and may help more patients get cured, largely by helping them stick to their medication schedule. While the researchers cannot say with absolute certainty that the probiotic is the direct cause of the higher cure rates, the combination of better adherence and higher success numbers makes a strong case for its use. The authors emphasize that because this was a look-back study rather than a new experiment where patients were randomly assigned, more rigorous testing is needed to confirm the finding. Nevertheless, the evidence gathered from this large group of real-world patients suggests that a simple addition of beneficial bacteria could be a helpful tool in the fight against a common and potentially dangerous infection.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.